Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer

Journal of Clinical Oncology

Volumn 25, Issue 31, 2007, Pages 4880-4886

  Chen, Changhu ^a   Kane, Madeleine ^a   Song, John ^a   Campana, John ^a   Raben, Adam ^a   Hu, Kenneth ^a   Harrison, Louis ^a   Quon, Harry ^a   Dancey, Janet ^a   Baron, Anna ^a   Said, Sherif ^a   Eckhardt, S Gail ^a   Raben, David ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEFITINIB;

ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BONE METASTASIS; BURNING SENSATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHASIA; ELECTROLYTE DISTURBANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEAD AND NECK CANCER; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERNATREMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LIVER METASTASIS; LUNG METASTASIS; MAINTENANCE THERAPY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PAIN; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RADIATION DERMATITIS; RADIATION DOSE; RASH; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TASTE DISORDER; TONGUE BURNING SENSATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BLEEDING; VOMITING; WOUND HEALING IMPAIRMENT; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES;

EID: 36849051467     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.9650     Document Type: Article

References (25)

1. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
2. Herbst RS, O'Reilly MS: The rationale and potential of combining novel biologic therapies with radiotherapy: Focus on non-small cell lung cancer. Semin Oncol 30:113-123, 2003
3. Shintani S, Li C, Mihara M, et al: Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 107:1030-1037, 2003
4. Akimoto T, Hunter NR, Buchmiller L, et al: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5:2884-2890, 1999
5. Shintani S, Kiyota A, Mihara M, et al: Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 (IRESSA), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Am J Clin Oncol 26:e150-e156, 2003
6. Ochs JS: Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys 58:941-949, 2004
7. Al-Hazzaa A, Bowen ID, Randerson P, et al: The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells. Cell Prolif 38:77-86, 2005
8. Magne N, Fischel JL, Dubreuil A, et al: Sequence-dependent effects of ZD1839 (Iressa) in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86:819-827, 2002
9. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000
10. Sirotnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000
11. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002
12. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002
13. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003
14. Cohen EE, Kane MA, List MA, et al: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11:8418-8424, 2005
15. Cohen EE: Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24:2659-2665, 2006
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Brizel DM, Albers ME, Fisher SR, et al: Hyper-fractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338:1798-1804, 1998
18. Ang KK, Harris J, Garden AS, et al: Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology group phase II trial 99-14. J Clin Oncol 23:3008-3015, 2005
19. Fu KK, Pajak TF, Trotti A, et al: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48:7-16, 2000
20. Herchenhorn D, Dias FL, Pineda RM, et al: Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 25:307s, 2007 (suppl 18S, abstr 6033)
21. Huang S, Armstrong EA, Benavente S, et al: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64:5355-5362, 2004
22. Kelly K, Chansky K, Gaspar LE, et al: Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J Clin Oncol 25:388s, 2007 (suppl 18S, abstr 7513)
23. Milas L, Fang FM, Mason KA, et al: Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 67:568-572, 2007
24. Cohen EE, Haraf DJ, Stenson KM, et al: Integration of gefitinib (G), into a concurrent chemoradiation (CRT) regimen followed by G adjuvant therapy in patients with locally advanced head and neck cancer (HNC): A phase II trial. J Clin Oncol 23:501s, 2005 (suppl 16S, abstr 5506)
25. Ahmed SM, Cohen EE, Haraf DJ, et al: Updated results of a phase II trial integrating gefitinib (G) into concurrent chemoradiation (CRT) followed by G adjuvant therapy for locally advanced head and neck cancer (HNC). J Clin Oncol 25:306s, 2007 (suppl 18S, abstr 6028)